Key result
Mechanical circulatory support with left ventricular assist devices significantly improves survival and quality of life in appropriately selected patients with end-stage heart failure.
Answers are grounded in this paper and cite their sources.
Left ventricular assist devices significantly improve survival and quality of life in patients with end-stage HFrEF and should be considered after thorough evaluation.
Mechanical circulatory support has emerged as an important therapy for advanced heart failure, with more than 18,000 continuous flow devices implanted worldwide to date. These devices significantly improve survival and quality of life and should be considered in every patient with end-stage heart failure with reduced ejection fraction who has no other life-limiting diseases. All candidates for device implantation should undergo a thorough evaluation in order to identify those who could benefit from device implantation. Long-term management of ventricular assist device patients is challenging and requires knowledge of the characteristic complications with their unique clinical presentations.
No takes yet. Share an insight, caveat, or question.
Birati et al. (2015) conducted a review in Advanced Heart Failure. Left Ventricular Assist Devices (LVAD) was evaluated. Mechanical circulatory support with left ventricular assist devices significantly improves survival and quality of life in appropriately selected patients with end-stage heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: